122 related articles for article (PubMed ID: 16472164)
1. Fatty acid amide hydrolase: a potential target for next generation therapeutics.
Maccarrone M
Curr Pharm Des; 2006; 12(6):759-72. PubMed ID: 16472164
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
Fezza F; De Simone C; Amadio D; Maccarrone M
Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
[TBL] [Abstract][Full Text] [Related]
3. New insights into endocannabinoid degradation and its therapeutic potential.
Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoids and their involvement in the neurovascular system.
Battista N; Fezza F; Maccarrone M
Curr Neurovasc Res; 2004 Apr; 1(2):129-40. PubMed ID: 16185189
[TBL] [Abstract][Full Text] [Related]
5. Partial QSAR analysis of some selected natural inhibitors of FAAH suggests a working hypothesis for the development of endocannabinoid-based drugs.
Dainese E; Gasperi V; Maccarrone M
Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):709-14. PubMed ID: 16375688
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis.
Maccarrone M; Finazzi-Agró A
Cell Death Differ; 2003 Sep; 10(9):946-55. PubMed ID: 12934069
[TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system in ageing: a new target for drug development.
Paradisi A; Oddi S; Maccarrone M
Curr Drug Targets; 2006 Nov; 7(11):1539-52. PubMed ID: 17100593
[TBL] [Abstract][Full Text] [Related]
8. The endocannabinoid system in neurodegeneration.
Battista N; Fezza F; Finazzi-Agrò A; Maccarrone M
Ital J Biochem; 2006; 55(3-4):283-9. PubMed ID: 17274532
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids and their actions.
Maccarrone M; Finazzi-Agrò A
Vitam Horm; 2002; 65():225-55. PubMed ID: 12481549
[TBL] [Abstract][Full Text] [Related]
10. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
Vandevoorde S; Lambert DM
Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
[TBL] [Abstract][Full Text] [Related]
11. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
12. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
Vandevoorde S
Curr Top Med Chem; 2008; 8(3):247-67. PubMed ID: 18289091
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications.
Bisogno T; De Petrocellis L; Di Marzo V
Curr Pharm Des; 2002; 8(7):533-47. PubMed ID: 11945157
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines.
Mulder AM; Cravatt BF
Biochemistry; 2006 Sep; 45(38):11267-77. PubMed ID: 16981687
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.
Glaser ST; Deutsch DG; Studholme KM; Zimov S; Yazulla S
Vis Neurosci; 2005; 22(6):693-705. PubMed ID: 16469181
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
19. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation.
Alvarez-Jaimes LJ; Palmer JA
Curr Pharm Biotechnol; 2011 Oct; 12(10):1644-59. PubMed ID: 21466449
[TBL] [Abstract][Full Text] [Related]
20. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
